DrDiana Barb

A Phase 3, Open Label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching from the Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adult Participants with Obesity or Overweight